Zydus Lifesciences gets USFDA’s approval for Fludrocortisone Acetate Tablets

18 Oct 2024 Evaluate

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Fludrocortisone Acetate Tablets USP, 0.1 mg.

Fludrocortisone acetate tablets are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome. Fludrocortisone acetate tablets will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad.

Fludrocortisone acetate tablets had annual sales of $19.9 million in the United States (IQVIA MAT July 2024). The group now has 400 approvals and has so far filed over 465 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

957.80 -14.90 (-1.53%)
30-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1882.20
Dr. Reddys Lab 1377.55
Cipla 1520.65
Lupin 2309.65
Zydus Lifesciences 957.80
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.